Physician profile
Damon Lee
NPI 1922095256
$15,002.64
in general payments reported to CMS, 2019-2025
28 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,941 · 2020: $1,579 · 2021: $2,200 · 2022: $1,477 · 2023: $1,926 · 2024: $2,065 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,804 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,803.56 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,028.01 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $2,870.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,653.79 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,064.96 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Glaxosmithkline, LLC. | $856.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $671.14 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $642.00 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $629.48 | 2019-2025 | |
| Abbvie INC. | $529.96 | 2019-2025 | |
| Pfizer INC. | $515.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $501.35 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $441.90 | 2019-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $384.22 | 2019-2025 | Verquvo |
| Arbor Pharmaceuticals, INC. | $191.21 | 2019-2021 | |
| Amgen INC. | $163.83 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $157.19 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Amarin Pharma, INC. | $118.11 | 2019-2021 | |
| Optinose US, INC. | $95.63 | 2019 | |
| Astellas Pharma US INC | $89.15 | 2020-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $63.37 | 2024-2025 | Zoryve |
| Biogen, INC. | $58.75 | 2021 | |
| Dexcom, INC. | $51.50 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $28.77 | 2025 | Voquezna |
| Allergan, INC. | $22.31 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.50 | 2019 | |
| Daiichi Sankyo INC. | $15.25 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.